Navigation Links
Ample Supplies of Relenza Available as Flu Season Peaks
Date:3/2/2009

RESEARCH TRIANGLE PARK, N.C., March 2 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) is prepared with ample supplies of the influenza antiviral medication RELENZA(R) (zanamivir) Inhalation Powder (www.RELENZA.com) to meet public health needs as the current influenza season peaks. According to newly updated influenza activity data (http://www.cdc.gov/flu/weekly/) released by the Centers for Disease Control and Prevention (CDC), the flu virus is widespread in 27 states.

Relenza is a preferred medication for all circulating subtypes of influenza virus according to CDC interim guidance, issued on December 19th, 2008 http://www2a.cdc.gov/HAN/ArchiveSys/ViewMsgV.asp?AlertNum=00279. Based on the latest CDC influenza activity data, the influenza A (H1N1) virus appears to be the most prevalent strain circulating this flu season in the United States, but concern of antiviral resistance persists with the influenza A (H1N1) strain. According to CDC surveillance data, RELENZA has not shown resistance to the influenza A (H1N1) virus or any of the other CDC-tested influenza virus subtypes circulating this flu season. Clinical significance cannot be inferred from this surveillance data.

Pharmacies can obtain RELENZA from their wholesalers.

About RELENZA

RELENZA is a medicine for the treatment of influenza and for reducing the chance of getting the flu in community and household settings. It belongs to a group of medicines called neuraminidase inhibitors. These medications attack the influenza virus and prevent it from spreading inside your body. RELENZA treats the cause of influenza at its source, rather than simply masking the symptoms. RELENZA is delivered via oral inhalation using a Diskhaler. Step-by-step instructions for proper use of the Diskhaler are available at www.RELENZA.com, including a short instruction video.

Important Safety Information

RELENZA is not recommended for treatment or prophylaxis of influenza in individuals with underlying airways disease (such as asthma or chronic obstructive pulmonary disease).

Serious cases of bronchospasm, including fatalities, have been reported during treatment with RELENZA in patient with and without underlying airways disease. Many of these cases were reported during postmarketing and causality was difficult to assess.

If use of RELENZA is considered for a patient with underlying airways disease, the potential risks and benefits should be carefully weighed. Use in these patients should be done only under conditions of careful monitoring or respiratory function, close observation, and appropriate supportive care including availability of fast-acting bronchodilators.

Discontinue RELENZA and initiate appropriate treatment if an allergic reaction occurs or is suspected.

Patients with influenza, particularly pediatric patients, may be at an increased risk of seizures, confusion, or abnormal behavior early in their illness. Monitor for signs of abnormal behavior.

Safety and efficacy have not been demonstrated in patients with high-risk underlying medical conditions.

RELENZA has not been proven effective for prophylaxis of influenza in the nursing home setting.

RELENZA is not a substitute for early influenza vaccination on an annual basis as recommended by the Centers for Disease Control's Immunization Practices Advisory Committee.

Influenza viruses change over time. Emergence of resistance mutations could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use RELENZA.

GlaxoSmithKline: A Leader in Flu

GlaxoSmithKline has an active research and development program targeted at both seasonal and pandemic flu and has recently invested more than $2 billion to expand capacity for manufacturing its flu vaccines FLUARIX(R) [Influenza Virus Vaccine] and FLULAVAL(TM) [Influenza Virus Vaccine] and its antiviral flu medication RELENZA. GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GlaxoSmithKline at www.gsk.com.

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2007.


'/>"/>
SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. 1 sample examined by 1,000 pathologists -- how and why?
2. Jon R. Wampler Joins Portico Systems Board of Directors
3. Parents Encouraged to Set an Example for Their Teens and Help Stop Underage Drinking
4. ConsumerLab.com Study On Revatrol NOT Based on Current Formulation - the Revatrol Sample Used Was More Than Nine Months Out-Of-Date, says Renaissance Health Publishing
5. Leading by Example: Blue Care Network of Michigan Shows How Employers Can Improve Employee Wellness
6. Most Free Drug Samples Go to Wealthy and Insured
7. Forsyth launches 1-of-a-kind core service to enable rapid identification of bacterial samples
8. Childrens HeartLink Benefits From Valentines Day Love Knot Sampler Sales by Kim & Scotts Gourmet Pretzels
9. Childrens HeartLink(R) to Benefit From Sales of Kim & Scotts Gourmet Pretzels(R) Valentines Day Love Knot Sampler(TM)
10. Scientists using laser light to detect potential diseases via breath samples, says new study
11. Press Statement: Roche Affirms That Tamiflu(R) is in Ample Supply Nationwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... , ... The Woodlands at John Knox Village , Florida’s first Life ... living and healing, celebrated its grand opening, today. The Woodlands at John Knox Village ... Empowered Staff. , “This is an incredibly fulfilling time for John Knox Village as ...
(Date:5/26/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... global clinical supply services, today announced two key appointments and the opening of ... strategic growth plans in the Asia Pacific region. , Howard Kim has joined ...
(Date:5/26/2016)... ... May 26, 2016 , ... Memorial Day Weekend marks the unofficial start ... is sharing tips to make sure your family and vehicle are ready to hit ... there may be 439 deaths and an additional 50,500 serious injuries from motor vehicle ...
(Date:5/26/2016)... ... May 26, 2016 , ... North Cypress Medical Center ... Golf Club in Cypress. With the help of community partners, the event organizers raised ... renews hope for wounded service members and their families through health, wellness, and therapeutic ...
(Date:5/26/2016)... ... May 26, 2016 , ... Eugene Batelli, D.P.M., ... with his wonderful accolades and stellar patient reviews, Dr. Batelli continues to be ... Dr. Eugene Batelli is a highly trained Podiatric Surgeon who specializes in treating ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... According to market research "Global ... Demand Forecast to 2022 - Industry Insights by Type ... by P&S Market Research, the global insulin delivery device ... it is expected to grow at a CAGR of ... segment is expected to witness the fastest growth at ...
(Date:5/25/2016)... , May 25, 2016 Digital Health ... to it by the US Patent and Trademark ... technology includes proprietary processes for electronic opt-­in and ... and wellness programs, HIPAA compliance and otherwise. ... "Our technology allows for ...
(Date:5/25/2016)... May 25, 2016 ReportsnReports.com ... research report that provides an overview on therapeutic ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ... key players involved in the therapeutic development for ...
Breaking Medicine Technology: